13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001482416
Total reported value
$604.3M
$604.3M
48 檔
32.4%
According to the latest 13F quarterly dataset, Sio Capital Management, LLC managed an equity portfolio of $604.3M at the end of Q2 2024, spanning 48 distinct U.S. exchange-listed positions.
During Q2 2024, Sio Capital Management, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | INSM | Insmed Inc | Stock-Healthcare | 24.71% | — | — | |
| 2 | LH | Labcorp Holdings Inc | Stock-Healthcare | 13.54% | — | — | |
| 3 | TFX | Teleflex Inc | Stock-Healthcare | 6.32% | -1.63% | EXIT | |
| 4 | ZBH | Zimmer Biomet Holdings Inc | Stock-Healthcare | 4.56% | +1.06% | +109.36% | |
| 5 | SNN | Smith & Nephew PLC -spon Adr | Stock-Other | 3.89% | — | — | |
| 6 | PCRX | Pacira Biosciences Inc | Stock-Other | 3.53% | — | +306.70% | |
| 7 | OGN | Organon & Co | Stock-Healthcare | 3.41% | -0.74% | EXIT | |
| 8 | GSK | Gsk Plc-spon Adr | Stock-Healthcare | 3.25% | +0.74% | +18.43% | |
| 9 | CRBP | Corbus Pharmaceuticals Holdi | Stock-Other | 2.76% | — | — | |
| 10 | VXRT | Vaxart Inc | Stock-Other | 2.67% | — | — | |
| 11 | TYRA | Tyra Biosciences Inc | Stock-Other | 2.60% | +0.35% | +12.05% | |
| 12 | ABT | Abbott Laboratories | Stock-Healthcare | 2.52% | -0.82% | — | |
| 13 | CI | THE Cigna Group | Stock-Healthcare | 2.40% | +2.63% | NEW | |
| 14 | KVUE | Kenvue Inc | Stock-Consumer Staples | 2.39% | — | — | |
| 15 | IRON | Disc Medicine Inc | Stock-Other | 2.34% | -0.60% | EXIT | |
| 16 | ERAS | Erasca Inc | Stock-Other | 1.84% | -0.01% | EXIT | |
| 17 | ✓ | Biodesix Inc | Stock-Other | 1.80% | — | — | |
| 18 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 1.26% | — | +24.37% | |
| 19 | ANIP | Ani Pharmaceuticals Inc | Stock-Other | 1.24% | -1.60% | -17.87% | |
| 20 | BLCO | Bausch + Lomb CORP | Stock-Other | 1.19% | — | — | |
| 21 | PMVP | Pmv Pharmaceuticals Inc | Stock-Other | 1.19% | +0.03% | — | |
| 22 | ZYME | Zymeworks Inc | Stock-Other | 1.13% | — | — | |
| 23 | BBIO | Bridgebio Pharma Inc | Stock-Healthcare | 0.86% | — | -38.39% | |
| 24 | APGE | Apogee Therapeutics Inc | Stock-Other | 0.83% | — | — | |
| 25 | CNTX | Context Therapeutics Inc | Stock-Other | 0.72% | -0.34% | EXIT | |
| 26 | ✓ | Modular Med Inc | Stock-Other | 0.66% | — | — | |
| 27 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.64% | — | -22.26% | |
| 28 | ENTA | Enanta Pharmaceuticals Inc | Stock-Other | 0.62% | -0.07% | EXIT | |
| 29 | ✓ | Third Harmonic Bio Inc | Stock-Other | 0.57% | — | — | |
| 30 | NUVB | Nuvation Bio Inc | Stock-Other | 0.53% | — | -50.00% | |
| 31 | SPRY | Ars Pharmaceuticals Inc | Stock-Other | 0.50% | — | -59.37% | |
| 32 | VTYXUSD | Ventyx Biosciences Inc | Stock-Other | 0.49% | — | +106.06% | |
| 33 | CMPS | Compass Pathways PLC | Stock-Other | 0.48% | -1.19% | EXIT | |
| 34 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 0.40% | — | -74.90% | |
| 35 | ASNSUSD | X4 Pharmaceuticals Inc | Stock-Other | 0.39% | — | -30.34% | |
| 36 | PRLD | Prelude Therapeutics Inc | Stock-Other | 0.33% | — | — | |
| 37 | APRE | Aprea Therapeutics Inc | Stock-Other | 0.30% | — | — | |
| 38 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.26% | — | — | |
| 39 | AVTX | Avalo Therapeutics Inc | Stock-Other | 0.24% | — | +603.95% | |
| 40 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 0.19% | -0.08% | EXIT | |
| 41 | BOLD | Boundless Bio Inc | Stock-Other | 0.17% | -0.03% | EXIT | |
| 42 | VSTM | Verastem Inc | Stock-Other | 0.11% | — | — | |
| 43 | ✓ | Nyxoah S A | Stock-Other | 0.10% | -0.02% | EXIT | |
| 44 | NXTCEUR | Nextcure Inc | Stock-Other | 0.06% | — | — | |
| 45 | ✓ | Aslan Pharmaceuticals LTD | Stock-Other | 0.02% | — | — | |
| 46 | HUMAW | Humacyte Inc-cw27 | Stock-Other | 0.02% | — | — | |
| 47 | RCKTW | Rocket Pharmaceuticals In-27 | Stock-Other | 0.01% | — | — | |
| 48 | ✓ | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Sio Capital Management, LLC reported a total U.S. public equity portfolio value of $604.3M across 48 disclosed positions in Q2 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including INSM, LH, TFX) accounted for 32.4% of total reported equity market value during Q2 2024.
During Q2 2024, Sio Capital Management, LLC's top holdings by market value included INSM (24.7%)、LH (13.5%)、TFX (6.3%). The largest single position, INSM, represented 24.7% of total portfolio value.
In Q2 2024, Sio Capital Management, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.